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Aim: To create an information resource concerning multifactorial oncological diseases of the female reproductive system. Materi-
als and Methods: A comprehensive search of the literature in the PubMed and Ukrainian scientific sources published from 
1995 to 2014 and the results of researches performed in R.E. Kavetsky Institute of Experimental Pathology, Oncology and Ra-
diobiology, National Academy of Sciences of Ukraine. Development environment of information resource “Multifactorial onco-
logical disease” was Borland Delphi. Results: The information content of web page concerning cancers of the female reproductive 
system was posted in the information resource “Multifactorial oncological disease”. The assessment algorithm of genetic contribu-
tion to cancers of the female reproductive system and recurrent risk of cancer development in families have been described. These 
algorithms can be used in assessment of contribution of genetic and environmental factors in the development of malignant tumors.
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Despite progress in anticancer campaign in Ukraine, 
this problem is still relevant for public health.  According 
to the data of epidemiological studies of National Can-
cer Institute of Ukraine, overall incidence of malignant 
neoplasms (MN) in Ukraine has increased in 2011 com-
pared with 2010 on 2.7% among female population and 
on 1.6% among men. When characte rizing structure 
of MN morbidity in 2011, we can note that MN of breast, 
corpus uteri, uterine cervix, colorectal cancer and 
non-melanoma skin MN take rank places among 
women — 58.8% and the most widespread MN in men 
are prostate gland cancer, gastric, colorectal, lung 
cancer, non-melanoma skin MN — 57.8% [1] .
To date, it is beyond the question that cancer prob-
lem can be solved only on conditions of development 
of measures of cancer disease prophylaxis, increase 
of level of timely diagnostics of MN and carrying out 
of adequate therapy. One more condition which has 
essential significance for improvement of treatment 
results is providing of patient care institutions with 
modern equipment and instrumentation and increase 
of level of vocational training of oncologists.
Subsidiary, and in series of cases, crucial sig-
nificance for timely diagnostics and determination 
of treatment tactics have modern knowledge which 
can be obtained in systematized, formalized and 
structured forms.
However, dynamic development of computer 
information technologies in medical and biological 
spheres can both accelerate and complicate obta ining 
and interpretation of required information on given 
problem in connection with its permanent updating, 
representation in various formats and by different 
stage of detailing.
For this reason, important element of treatment-
and-diagnostic process is creation of information 
resource as theoretical basis with system of hyperlinks 
on Internet resources for effective access to informa-
tion and its use as basis for development of prophy-
laxis system and algorithms of diagnostics of cancer 
diseases which would include methods of assessment 
of hereditary and recurrent risk of MN of different 
genesis.
Aim of the research was to create information 
resource on multifactorial cancer diseases of female 
reproductive system which occurrence has polygenic 
nature.
METHODS 
Systemic analysis of the problem, generalization 
of information, structural and functional study of sub-
ject for the application of knowledge in the context 
of multifactorial cancer diseases have been used. 
Development environment of information resource 
was Borland Delphi. For the functioning of system, 
operating platform Windows and dynamic libraries 
of Delphi resources have been used.
RESULTS AND DISCUSSION 
Work on creation of information resource “Multifac-
torial cancer diseases” has been divided in the stages 
by degree of topicality and sequence of their perfor-
mance which included analysis of information (gene-
ralization and systematization of theoretical knowledge 
of foreign and national scientific literature as well 
as results of own studies of stuff of the R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology of NAS of Ukraine, choice of conception 
of information presentation), development of struc-
ture, programming and entry of the information.
Information on cancer diseases of female repro-
ductive system, namely risk factors, genetic features 
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of MN, prognostic markers and prophylactic measures 
concerning occurrence of cancer diseases has been 
analyzed.
On the basis of analysis, a structure has been 
developed which included the following parts for 
each localization: classification of malignant tumors 
by TNM (2009), FIGO (2009) and WHO (2014) and their 
phenotype parameters, algorithm of diagnostics and 
prognostic markers.
According to the structured information concern-
ing endo- and exogenous factors of predisposition 
to MN, it has been determined that most of cancers 
of the female reproductive system (CFRS) are multi-
factorial diseases. It means that occurrence of such 
cancer diseases is connected both with genetic factors 
and with impact of various bad environmental factors 
which cause the disorders of systems of regulation 
of differentiation and proliferation of cells. At that, 
multifactorial inheritance and part of hereditary factor 
varies for individuals of different sex by age, for tumors 
of different genesis and geographic regions [2–5]. 
When analyzing inheritance of breast cancer (BC), 
ovarian cancer (OC) and cancer of the uterine cervix 
(CUC) within the framework of multifactorial model, 
genetic determinant in development of these diseases 
constitutes 55.7 ± 2.4%; 66.8 ± 6.3% and 2.9 ± 2.6%, 
correspondingly. These data show that, on the one 
hand, there is different impact of genetic and envi-
ronmental factors on development of the disease, 
and, on the other hand, they are heterogeneous [3–5].
Some other researchers have determined certain 
relation between malignant process and individual 
predisposition to occurrence of tumor. For instance, 
we shall focus on some important results of study, 
namely occurrence of 85–90% of BC cases is con-
nected with epigenetic changes in BRCA1 gene [6, 7], 
in 15–43% of cases — with amplification of HER2/neu 
(ErbB-2) gene [8], and in 20% of cases — with spon-
taneous mutations of ТР53 gene and in 12.0% — with 
mutations of MMR family genes [9]. It should be men-
tioned that 5–10% of cases of OC develops on the 
background of germinal mutations of series of genes-
suppressors (BRCA1/BRCA2, TP53, CHEK2, PTCH, 
VHL, NBS1), genes of FANC and MMR family which are 
responsible for reparation of unpaired bases of DNA 
within the limits of series of family cancer syndromes. 
It has been showed that risk of OC in women with Lynch 
syndrome II constitutes 9–12% [10–13]. At the same 
time, decrease of expression of BRCA1 gene (in result 
of epigenetic changes or alternative splicing) has been 
noted in 65–82% of sporadic cases of OC [14, 15]. Be-
sides mentioned above, in 50–66% of malignant ova-
rian neoplasms, inactivation (mutations or epigenetic 
changes) of gene-suppressor TP53 [16–18] is being 
determined, in 28.0–40.0% — decrease of expression 
of PTEN gene [19], amplification of genes Her2/neu 
(ЕrbB-2) — in 16–32%, EGFR (с-erbB-1) — in 9–17% 
of cases and in 15% of cases — mutation changes 
of KRAS gene [20, 21].
Our studies have determined significant decrease 
of expression of receptors of estrogens and proges-
terone in highly proliferative and low differentiated 
serous OC [22].
Molecular aspects of development of endometrial 
malignant tumors are broadly covered in literature. For 
instance, occurrence of endometrioid adenocarci-
noma in 83% of cases is associated with inactivation 
of PTEN gene (mutations or deletions), mutations 
of genes РІK3СА (26–36%), KRAS (10–30%), — 
β-catenin/CTNNB1 (14–44%) and TP53 (10–20%), 
inactivation of р16INK4a (10%), amplification of Her2/
neu (10–30%) and loss of E-cadherin (10–20% 
of cases) [23].
In contrast to previously mentioned, in serous ma-
lignant endometrial tumors, genetic changes in listed 
above genes are to be found with other frequency. 
Mostly in such tumors are detected mutations in gene-
suppressor TP53 (90%), loss of E-cadherin is deter-
mined in 60–90% of cases, inactivation of р16INK4a 
in 40–45% of tumors, amplification of Her2/neu 
in 18–80% of observations. Along with it, changes 
in functioning of PTEN gene is being observed only 
in 11% of cases, mutations in РІK3СА — 5%, KRAS 
and CTNNB1 are detected in 5–10% of tumors [23]. 
It has been showed that increased risk of endometrial 
cancer (EC) and early debut of colorectal cancer are 
associated with family history of women both without 
mutation of genes of MMR family and with mutations 
in these genes within the limits of Lynch syndrome, 
have general hereditary and environmental factors [24, 
25]. Despite contribution of genetic component 
to occurrence of CUC is quite insignificant (2.9%), but 
in tumor cells of uterine cervix spontaneous mutations, 
deletions or epigenetic changes of genes-suppressors 
ST3, FHIT, proto-oncogenes EGFR, FGFR3 and  c-MYC 
and oncogene c-FOS are registered [5, 26–30]. 
Along with this, it has been determined to date that 
le ading role in development of CUC belongs to human 
papilloma virus (HPV) [31–33], oncogenes EGFR, 
FGFR3 та c-MYC and oncogene c-FOS [5, 26–30].
Some researchers state that infection agents, 
as HPVs, are risk factors of occurrence not only of CUC, 
but also have certain pathogenic role in deve lopment 
of EC, OC and BC [34–39]. It can be confirmed not only 
by results of our previous studies which have showed 
that in the condition of infection by virus, tumor cells 
of ovary are characterized by low expression of pro-
teins — tumor suppressors р53 and pRb [40–42] that 
is typical for HPV-associated neoplasms.
It is known that “trigger” of pathological process 
can be both genetic and environmental factors as-
sociated with high risk of MN. Vector of development 
of MN is determined depending on individual genetic 
constitution of organism. For instance, along with im-
pact of biological factors influencing the occurrence 
of cancer diseases, potential ecological risk factors 
which are connected with environment in concrete 
geographical region and physical and chemical agents 
cannot be excluded [43–46].
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At the same time, question concerning assessment 
of MN risk still remains open, namely question con cerning 
contribution of hereditary and environmental factors 
to development of MN, exactly CFRS, criteria of individual 
prognosis of this pathology are also not determined.
In part “Prognostic markers”, rates of unfavorable 
clinical course of disease, measures of prophylaxis 
according to the each localization of CFRS are given.
Part “Algorithm of diagnostics” included informa-
tion according with subsections: clinical criteria; labo-
ratory indexes; risk factors. The latter includes develo-
ped by us algorithm of assessment of risk of disease, 
to be exact cancer, which is located in information field 
of the resource “Multifactorial cancer diseases”. As-
sessments of genetic predisposition to cancer patho-
logy (Fig. 1) and recurrent risk of disease in progenies 
(Fig. 2) are carried out by clinical and genealogical data 
obtained at individual inquiry of persons or patients 
with histologically verified diagnosis.
Determination of population frequency of disease
Determination of number of healthy/affected individuals 
in pair “parents-children” by clinical and genealogical data
Calculation of interclass correlation coefficients of frequency of disease 
between close proband’s relatives
Determination of hereditary model: monogenic/multifactorial
Determination of number of correlation pairs 
between proband’s relatives relatives
Determination of correlation coefficients for component division 
of dispersion
Fig. 1. Algorithm of assessment of contribution of genetic and 
environmental components to predisposition to disease
Algorithm 1 includes:
• determination of population frequency in calcu-
lated time period by data on population size and 
population morbidity in corresponding geographi-
cal region;
• determination of frequency of occurrence of di-
sease and number of affected relatives by principles 
of analysis of individual’s pedigree (proband’s);
• determination of relations between proband’s rela-
tives (genetic-correlation analysis) for assessment 
of genetic predisposition to disease;
• calculation of correlation coefficients between 
relatives before manifestation of disease within 
the limits of monogenic model (alternative distribu-
tion of predisposition to disease) and multifactorial 
model (quasi-continuous distribution);
• carrying out of genetic analysis of multifactorial 
signs (component analysis);
• assessment of correlative contribution of genetic 
and environmental components to occurrence 
of disease taking into account coefficient of affinity 
using procedure of component division of pheno-
type dispersion for determination of role of heredi-
tary factor by proband’s pedigrees in determination 
of occurrence of disease.
Determination of population frequency of disease
Selection by clinical and genealogical data of group of patients 
depending on type of marriage of proband’s parents (mother-father) 
and association of tumors proband-sibs
♀ Normal × Normal ♂ ♀ Normal × Affected ♂♀ Affected × Normal ♂ ♀ Affected × Affected ♂
Determination of data for calculation of segregation frequencies: number 
of probands; total number of children; number of affected children; 
number of families
Calculation of segregation frequencies by type of registration of families
Comparison of empirical and theoretical segregation frequencies
Carrying out of test of monogenic autosomal inheritance: 
dominant/recessive model
Calculation of recurrent risk of occurrence of disease in descendants
Fig. 2. Algorithm of assessment of recurrent risk of disease 
in progenies
Algorithm 2 includes:
• determination of population frequency in calcu-
lated period of time by data on population size and 
population morbidity in corresponding geographi-
cal region;
• formation of groups according to clinical and ge-
nealogical information depending on type of mar-
riage of proband’s parents (normal or affected);
• determination of quantitative rates of normal-
affected persons in family;
• carrying out of segregation analysis: distribution of dis-
ease in series of generations according to monogenic 
(autosomal-dominant and autosomal-recessive type 
of inheritance) and polygenic (multifactorial) model 
with differentiating approach considering family history 
of cancer according to gene alogic data;
• comparison between empirical segregation fre-
quencies and theoretically expected frequencies 
for prognosticated type of inheritance;
• calculation of recurrent risk of disease in progenies 
based on segregation frequencies.
Practical use of algorithms 1 and 2 at clinical and 
genealogical examination of 142 patients with EC living 
in Kyiv region allowed obtaining the following results.
1. It was determined that the population frequency 
of EC in women of Kyiv region equaled to 0.26%.
2. Coefficient of genetic correlation between first 
degree relatives of proband with EC was 0.53 that 
corresponds to the quasi-continuous distribution 
of predisposition to CFRS.
3. Contribution of genetic factors in the develop-
ment of CFRS constituted 53.2 ± 5.6%, environmental 
factors — 46.8 ± 5.6%.
4. Quantitative indexes of association EC — CFRS 
were determined in sisters of proband consi dering 
the type of parents’ marriage: both parents are 
healthy — N×N (Normal-Normal) and one or both 
parents of proband are cancer-affected — N×A 
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(Normal-Affected) and A×A (Affected-Affected) 
and segregation frequency of cancer development 
in families was calculated. If proband has healthy 
parents — segregation frequency constitutes 1.89 ± 
0.009, cancer affected parents — 4.38 ± 0.034.
5. The model of inheritance on the basis of test-
ing of monogenic autosomal inheritance by Stu-
dent’s criterion was determined. The obtained in-
dexes exce eded critical values at level of significance 
t(5%) = 1.96, indicating that dominant and recessive 
models cannot be fully accepted.
6. The probability of CFRS development was calculat-
ed for probands’ descendants depending on the health 
of parents: for the first child of healthy parents, cancer 
risk constitutes 0.3%, and for the se cond child — 1.6%. 
In cancer affected parents, pro bability of cancer for the 
first child equals 13.5, for the second — 19.3%.
Thus, information resource “Multifactorial cancer 
diseases” provides effective access to the information 
concerning cancer diseases of polygenic nature with 
the aim to use them in scientific and practical activity 
in the field of cancer genetics.
The main technical parameters of information 
resource are that it is directed to the work both 
in auto nomous (network) and local version without 
limitation of number of users. In program, the mecha-
nism of direct editing of data in web-fields without 
use of additional editors of HTML-documents has 
been implemented. Organization of simple interface 
is adapted for users who are not specialists in the 
domain of information technologies.
Represented algorithm of assessment of contribu-
tion of genetic and environmental components to pre-
disposition to occurrence of diseases, including cancer, 
as well as recurrent risk of cancer in progenies, can 
be used as base for development and realization of pre-
ventive measures in medical and genetic consulting.
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